Vicor earnings land as options traders turn sharply bullish

VICR reports Q3 results today against a backdrop that has shifted materially since the prior note ten days ago: the stock has dropped a further 26% on the week, yet options positioning has swung decisively toward calls rather than puts.

The options signal is the sharpest change in the setup. The put/call ratio has fallen to 0.80, nearly three standard deviations below its 20-day mean of 1.00, the most bullish options skew in the past year for this stock. That is a dramatic reversal from the mild defensiveness noted ten days ago. The PCR touched its highest levels of the past month around October 5 to 7, above 1.09, before collapsing as the stock fell hard. The implication is that traders are buying calls into the weakness, not adding puts, which runs directly against the direction of the share price. Short interest, meanwhile, has continued its gentle retreat: at 6.6% of the free float on October 16, it is down from the late-September peak near 2.4 million shares and has edged lower each day this week. Borrow remains cheap at 0.53%, and availability at 662% of short interest is loose, confirming that the lending market carries no squeeze pressure.

The bull and bear debate centres almost entirely on the Q3 revenue print itself. Vicor flagged more than 30% sequential revenue growth when it disclosed a non-exclusive vertical power delivery agreement with an AI OEM, and analysts have been racing to keep up: Needham raised its target to $350 on October 1, citing Gen 5 product traction and expanding royalty streams. The Street consensus sits at a mean target of $393.75, roughly double the current price of $190.68. Bears point to the concentration risk that sits behind that growth story. A large portion of revenue depends on a handful of hyperscale and semiconductor customers, and the company filed three additional patent infringement suits on September 8, underlining both its technology dependence and the execution uncertainty that comes with an active litigation posture. The 14% one-month decline and this week's 26% fall suggest the market is already pricing in some scepticism about whether the guided ramp is on schedule.

Institutional positioning adds a further layer. T. Rowe Price is the most notable recent mover, having nearly doubled its stake to 9.8% of shares as of September 30, adding over two million shares last quarter. That is a material conviction bet from a long-only fund made into the same period when the stock was still trading well above current levels. Chairman and CEO Patrizio Vinciarelli, who controls 42% of shares outstanding, sold approximately $6.2 million of stock on October 2 under a pre-arranged 10b5-1 plan, routine given the plan's structure but worth noting at prices roughly 40% above where the stock trades today. The earnings history reinforces the downside-skew context: the last print in July produced a 5.9% one-day decline and a 16.8% fall over the following five days.

Today's print is therefore a direct test of whether the guided record revenue quarter has materialised on schedule, and whether the royalty contribution is wide enough to drive the gross margin expansion that underpins every analyst target above $300.